Assertio (ASRT) shares ended the last trading session 17.9% higher at $16.51. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This ...

Earlier in March 2026, Assertio Holdings, Inc. reported fourth-quarter 2025 revenue of US$13.54 million, down from US$32.18 million a year earlier, alongside a wider quarterly net loss of US$11.93 ...

Company Will Report Third Quarter Results on November 10, 2025 and Expects to Update Guidance Within the Current Range at That Time LAKE FOREST, Ill., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Assertio ...

CEO Mark L. Reisenauer emphasized a shift in Assertio’s growth strategy, stating the company will prioritize driving "significant revenue opportunity in our core asset, Rolvedon," and that "our prior ...

Assertio Holdings, Inc. (Nasdaq: ASRT) (“Assertio” or the “Company”) today announced the successful completion of its previously announced merger (the “Merger”) with Zydus Lifesciences Ltd. (“Zydus ...

Four months after calling for the resignation of four board members from Assertio Holdings, New York investment advisory firm Buxton Helmsley Group has flipped its long equity position into a short ...

Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), today announced that it has reached a mutual agreement with Garda Therapeutics, Inc. (“Garda”) to postpone the commencement of the ...

Assertio Holdings, Inc. is proactively engaging with investors by announcing the release date for its fourth quarter and full year 2024 financial results, which can enhance transparency and trust. The ...

Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), today announced that it has reached a mutual agreement with Garda Therapeutics, Inc. (“Garda”) to delay the launch of the ...

LAKE FOREST, Ill., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (ASRT) (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to ...

Assertio Therapeutics ASRT shares are trading higher on Thursday after the company reported better-than-expected Q4 sales results. Assertio reported Q4 EPS of $0.32 which missed the analyst consensus ...